Janssen Signs Collaboration and License Agreement with Cellular Biomedicine to Develop CAR-T Therapies

By Lalit Mishra

Pharma Deals Review: Vol 2023 Issue 5 (Table of Contents)

Published: 18 May-2023

DOI: 10.3833/pdr.v2023.i5.2784     ISSN: 1756-7874

Section: Licensing



In order to strengthen its chimeric antigen receptor (CAR)-T cell therapy portfolio, Janssen has entered into an agreement with Cellular Biomedicine to develop next-generation CAR-T cell therapies for treating B-cell malignancies...

This page is available to subscribers only.

Not a subscriber? Join here

Why should I subscribe?

Already Registered? Please login using the top left purple box.

Copyright: © IQVIA 2018

IQVIA™ Pharma Deals: PharmaDeals Review: Article Details